Aryaet al. [18] analyzed the gene expression profile of xenografts from bevacizumab-resistant glioblastoma multiforme (GBM) patients and found that several hub genes, includingUBE2C, were associated with GBM resistance to bevacizumab, suggesting that UBE2C might participate in regulating the drug resistance of glioma. The gene discussed is UBE2C; the disease is central nervous system cancer.